FIELD: medicine.
SUBSTANCE: invention concerns GSK-3 inhibitors of general formula (I), method for making thereof and based pharmaceutical compositions which can be used in medicine: 
formula I, where R1 means an organic group containing at least 8 atoms, chosen of C or O, including aromatic ring of phenyl, naphthyl or methylene dioxypjenyl, which is not bound directly with N through -C(O)- or oxygen; Ra, Rb, Rz, R3, R4, R5 and R6 represent hydrogen.
EFFECT: production of new biologically active compounds for treatment of GSK-3 mediated diseases.
28 cl, 13 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| GSK-3 INHIBITORS | 2006 |
|
RU2449998C2 |
| HETEROCYCLIC INHIBITORS OF GLYCOGEN SYNTHASE-KINASE GSK-3 | 2001 |
|
RU2294931C2 |
| SELECTIVE BUTYRYLCHOLIN ESTERASE INHIBITORS | 2005 |
|
RU2386627C2 |
| PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | 2011 |
|
RU2582338C2 |
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2429237C2 |
| TACRINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS | 2004 |
|
RU2402545C2 |
| SULTAM-BASED COMPOUND AND METHOD OF USE THEREOF | 2017 |
|
RU2741915C2 |
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2450000C2 |
| SIGMA-RECEPTOR INHIBITORS | 2005 |
|
RU2417987C2 |
| CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | 2014 |
|
RU2665709C2 |
